Literature DB >> 17409111

High plasma cholesteryl ester transfer protein levels may favour reduced incidence of cardiovascular events in men with low triglycerides.

Susanna E Borggreve1, Hans L Hillege, Geesje M Dallinga-Thie, Paul E de Jong, Bruce H R Wolffenbuttel, Diederik E Grobbee, Arie van Tol, Robin P F Dullaart.   

Abstract

AIMS: High cholesteryl ester transfer protein (CETP) concentrations are associated with increased risk of cardiovascular disease (CVD) in subjects with high triglycerides. We determined the relationship of plasma CETP with incident CVD in a population with relatively low triglycerides. METHODS AND
RESULTS: A nested case-control study was performed in men participating in the prospective PREVEND study, after exclusion of CVD, diabetes mellitus, and lipid-lowering drugs use at baseline. Plasma CETP was measured in 111 men who developed a cardiovascular event (cases) during follow-up and in 116 controls who remained free of CVD. Fasting total cholesterol (P < 0.001) and triglycerides (P < 0.001) were higher, HDL cholesterol was lower (P = 0.001), but CETP was similar in cases and controls (P = 0.39). Cox proportional hazards regression analysis showed that CVD risk tended to be lower with higher plasma CETP after adjustment for age and lipids (hazard ratio 0.84; 95% CI 0.69-1.03, P = 0.10). Plasma CETP was lower in cases than in controls (P = 0.05) with triglycerides < or = 1.38 mmol/L (median), but not with higher triglycerides. The age-adjusted hazard ratio for CVD was 0.46 (95% CI 0.24-0.90) in men with triglycerides < or = 1.38 mmol/L and CETP > 2.26 mg/L (median) compared with men with similarly low triglycerides and CETP < or = 2.26 mg/L. With higher triglycerides, the hazard ratio for CVD was similar in both CETP categories.
CONCLUSION: Relatively high plasma CETP may favour reduced CVD risk in the context of low triglycerides.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17409111     DOI: 10.1093/eurheartj/ehm062

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  14 in total

Review 1.  Novel HDL-directed pharmacotherapeutic strategies.

Authors:  Emil M Degoma; Daniel J Rader
Journal:  Nat Rev Cardiol       Date:  2011-01-18       Impact factor: 32.419

Review 2.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

3.  Monogenic causes of elevated HDL cholesterol and implications for development of new therapeutics.

Authors:  Daniel B Larach; Marina Cuchel; Daniel J Rader
Journal:  Clin Lipidol       Date:  2013-12

4.  Cholesteryl ester transfer protein, low density lipoprotein particle size and intima media thickness in patients with coronary heart disease.

Authors:  Katerina Tosheska; Danica Labudovic; Silvana Jovanova; Branko Jaglikovski; Sonja Alabakovska
Journal:  Bosn J Basic Med Sci       Date:  2011-08       Impact factor: 3.363

5.  Association of circulating cholesteryl ester transfer protein activity with incidence of cardiovascular disease in the community.

Authors:  Ramachandran S Vasan; Michael J Pencina; Sander J Robins; Justin P Zachariah; Guneet Kaur; Ralph B D'Agostino; Jose M Ordovas
Journal:  Circulation       Date:  2009-12-15       Impact factor: 29.690

6.  Plasma lipid transfer proteins and cardiovascular disease. The Framingham Heart Study.

Authors:  Sander J Robins; Asya Lyass; Robert W Brocia; Joseph M Massaro; Ramachandran S Vasan
Journal:  Atherosclerosis       Date:  2013-02-18       Impact factor: 5.162

7.  Altered composition of triglyceride-rich lipoproteins and coronary artery disease in a large case-control study.

Authors:  Paul N Hopkins; M Nazeem Nanjee; Lily L Wu; Michael G McGinty; Eliot A Brinton; Steven C Hunt; Jeffrey L Anderson
Journal:  Atherosclerosis       Date:  2009-05-22       Impact factor: 5.162

8.  Plasma lipid transfer enzymes in non-diabetic lean and obese men and women.

Authors:  Faidon Magkos; B S Mohammed; Bettina Mittendorfer
Journal:  Lipids       Date:  2009-02-06       Impact factor: 1.880

Review 9.  Low-normal thyroid function and novel cardiometabolic biomarkers.

Authors:  Lynnda J N van Tienhoven-Wind; Robin P F Dullaart
Journal:  Nutrients       Date:  2015-02-16       Impact factor: 5.717

10.  Serum Alkaline Phosphatase and Risk of Incident Cardiovascular Disease: Interrelationship with High Sensitivity C-Reactive Protein.

Authors:  Setor K Kunutsor; Stephan J L Bakker; Jenny E Kootstra-Ros; Ronald T Gansevoort; John Gregson; Robin P F Dullaart
Journal:  PLoS One       Date:  2015-07-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.